Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cephalothin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.98 |
| ▸ | TDP1 | Q9NUW8 | 7/20 | 0.98 |
| ▸ | NR1I2 | O75469 | 4/20 | 0.98 |
| ▸ | HPGD | P15428 | 3/20 | 0.98 |
| ▸ | CTDSP1 | Q9GZU7 | 2/20 | 0.98 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.98 |
| ▸ | SLC22A8 | Q8TCC7 | 2/20 | 0.98 |
| ▸ | SLC22A11 | Q9NSA0 | 2/20 | 0.98 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.98 |
| ▸ | POLB | P06746 | 3/20 | 0.82 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.82 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.82 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.82 |
| ▸ | MEN1 | O00255 | 2/20 | 0.82 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.82 |
| ▸ | LMNA | P02545 | 2/20 | 0.82 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.82 |
| ▸ | GLA | P06280 | 1/20 | 0.82 |
| ▸ | APEX1 | P27695 | 1/20 | 0.82 |
| ▸ | PKM | P14618 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cephalothin SCHEMBL10974577 | 0.99 | MAPT (1.00) | MAPTTDP1NR1I2HPGDCTDSP1 | |
| Cephalothin SCHEMBL2990 | 0.99 | MAPT (1.00) | MAPTTDP1NR1I2HPGDCTDSP1 | |
| Cephalothin SCHEMBL16072835 | 0.99 | MAPT (1.00) | MAPTTDP1NR1I2HPGDCTDSP1 | |
| Cephalothin SCHEMBL5791156 | 0.99 | MAPT (1.00) | MAPTTDP1NR1I2HPGDCTDSP1 | |
| Cephalothin SCHEMBL4394024 | 0.99 | MAPT (1.00) | MAPTTDP1NR1I2HPGDCTDSP1 | |
| Cephalothin SCHEMBL11039891 | 0.99 | MAPT (1.00) | MAPTTDP1NR1I2HPGDCTDSP1 | |
| Cephalothin SCHEMBL4319851 | 0.99 | MAPT (1.00) | MAPTTDP1NR1I2HPGDCTDSP1 | |
| Cephalothin SCHEMBL9159686 | 0.99 | MAPT (1.00) | MAPTTDP1NR1I2HPGDCTDSP1 | |
| Cephalothin SCHEMBL1624515 | 0.99 | MAPT (1.00) | MAPTTDP1NR1I2HPGDCTDSP1 | |
| Cephalothin SCHEMBL148784 | 0.98 | MAPT (0.98) | MAPTTDP1NR1I2HPGDCTDSP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11357835-B2 | Compositions and methods for the treatment or the prevention of E. coli infections and for the eradication or reduction of E. coli surfaces | GALENAGEN, LLC (US) | 2022-06-14 | — | — | US | disclosed |
| US-20200323965-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OR PREVENTION OF STAPHYLOCOCCUS AUREUS INFECTIONS AND FOR THE ERADICATION OR REDUCTION OF STAPHYLOCOCCUS AUREUS ON SURFACES | CURELON LLC | 2020-10-15 | — | — | US | disclosed |
| CN-105031628-B | Compositions and methods for treating or preventing oral infections caused by E.coli | 加尔纳根有限责任公司 | 2020-10-02 | — | — | CN | disclosed |
| US-10736946-B2 | Compositions and methods for treatment or prevention of Staphylococcus aureus infections and for the eradication or reduction of Staphylococcus aureus on surfaces | GALENAGEN, LLC (US) | 2020-08-11 | — | — | US | disclosed |
| CN-105664144-B | Compositions and methods for treating or preventing staphylococcus aureus infections and eradicating or reducing staphylococcus aureus on surfaces | 加尔纳根有限责任公司 | 2020-08-11 | — | — | CN | disclosed |
| EP-3351264-A1 | COMPOSITION COMPRISING PROTEASE, AMYLASE AND LIPASE | Galenagen, LLC (US) | 2018-07-25 | — | — | EP | disclosed |
| US-20180104315-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OR THE PREVENTION OF E. COLI INFECTIONS AND FOR THE ERADICATION OR REDUCTION OF E. COLI SURFACES | CURELON LLC | 2018-04-19 | — | — | US | disclosed |
| EP-3064217-B1 | COMPOSITIONS COMPRISING PROTEASE, AMYLASE AND LIPASE FOR USE IN THE TREATMENT OF STAPHYLOCOCCUS AUREUS INFECTIONS | GALENAGEN LLC (US) | 2018-04-18 | — | — | EP | disclosed |
| US-9895427-B2 | Compositions and methods for the treatment or the prevention of E. coli infections and for the eradication or reduction of E. coli surfaces | GALENAGEN, LLC (US) | 2018-02-20 | — | — | US | disclosed |
| EP-3064217-A1 | COMPOSITIONS COMPRISING PROTEASE, AMYLASE AND LIPASE FOR USE IN THE TREATMENT OF STAPHYLOCOCCUS AUREUS INFECTIONS | Curelon LLC (US) | 2016-09-07 | — | — | EP | disclosed |
| US-7960505-B2 | Lantibiotics and uses thereof | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2011-06-14 | — | — | US | disclosed |
| WO-2010080830-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF STAPHYLOCOCCUS AUREUS INFECTIONS AND FOR THE ERADICATION OR REDUCTION OF STAPHYLOCOCCUS AUREUS ON SURFACES | CUREMARK LLC (US) | 2010-07-15 | — | — | WO | disclosed |
| WO-2010080835-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OR THE PREVENTION ORAL INFECTIONS BY E. COLI | CUREMARK LLC (US) | 2010-07-15 | — | — | WO | disclosed |
| EP-2176284-A2 | LANTIBIOTICS AND USES THEREOF | Regents Of The University Of Minnesota (US) | 2010-04-21 | — | — | EP | disclosed |
| WO-2009058440-A2 | LANTIBIOTICS FROM BIFIDOBACTERIUM LONGUM AND USES THEREOF | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2009-05-07 | — | — | WO | disclosed |
| US-20090068121-A1 | LANTIBIOTICS AND USES THEREOF | MINNESOTA, REGENTS OF THE UNIVERSITY OF | 2009-03-12 | — | — | US | disclosed |
| EP-1585532-A4 | TOPICAL ANTI-INFECTIVE FORMULATIONS | BIOSYNEXUS INC (US) | 2008-09-24 | — | — | EP | disclosed |
| EP-1585532-A2 | TOPICAL ANTI-INFECTIVE FORMULATIONS | Biosynexus Incorporated (US) | 2005-10-19 | — | — | EP | disclosed |
| US-20040192581-A1 | Topical anti-infective formulations | BIOSYNEXUS INCORPORATED | 2004-09-30 | — | — | US | disclosed |
| WO-2004052308-A2 | TOPICAL ANTI-INFECTIVE FORMULATIONS | BIOSYNEXUS INCORPORATED (US) | 2004-06-24 | — | — | WO | disclosed |